ストックスクリーナーアプリを入手
15.01
1.21%
0.18
アフターアワーズ：
15.08
0.07
+0.47%
Regenxbio Inc (RGNX) 最新ニュース
Regenxbio Inc outlines gene therapy pipeline as Nasdaq-listed biotech stays focused on long-term gro - AD HOC NEWS
First Patient Dosed in Phase 2b/3 NAAVIGATE Trial of Gene Therapy Surabgene Lomparvovec in Diabetic Retinopathy - CGTLive®
Regenxbio CMO Steve Pakola sells $29,476 in common stock - Investing.com
Form 4 Regenxbio Inc For: 6 July By Investing.com - Investing.com Canada
REGENXBIO (RGNX) CEO logs ESPP share acquisitions and tax-withholding stock disposition - Stock Titan
REGENXBIO (RGNX) CMO Pakola exercises options and sells 2,161 shares under plan - Stock Titan
REGENXBIO (RGNX) completes employee option exchange, grants 775,401 replacement options - Stock Titan
RGNX SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno - The National Law Review
REGENXBIO Inc updates pipeline strategy as gene therapy sector evolves - AD HOC NEWS
Regenxbio Insider Sold Shares Worth $688,756, According to a Recent SEC Filing - marketscreener.com
Regenxbio CMO Steve Pakola sells $688,755 in company stock. By Investing.com - Investing.com Nigeria
[Form 4] REGENXBIO Inc. Insider Trading Activity - Stock Titan
Regenxbio CMO Steve Pakola sells $688,755 in company stock. - Investing.com
Form 4 Regenxbio Inc For: 1 July By Investing.com - Investing.com Canada
Regenxbio Chief Medical Officer Sold Shares Worth Over $688K - TradingView
Proposed 43,206-share sale for RGNX (NASDAQ: RGNX) tied to option exercise - Stock Titan
H.C. Wainwright reiterates Regenxbio stock rating on trial milestone By Investing.com - Investing.com South Africa
REGENXBIO (RGNX) amends Schedule TO to update employee option exchange content - Stock Titan
H.C. Wainwright Maintains Regenxbio(RGNX.US) With Buy Rating, Maintains Target Price $26 - Moomoo
H.C. Wainwright reiterates Regenxbio stock rating on trial milestone - Investing.com
REGENXBIO Inc.(NasdaqGS: RGNX) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
symbol__ Stock Quote Price and Forecast - CNN
REGENXBIO Inc.(NasdaqGS: RGNX) added to Russell 2500 Growth Benchmark - marketscreener.com
REGENXBIO doses first patient in DR trial - grafa.com
Regenxbio doses first patient in diabetic retinopathy trial By Investing.com - Investing.com Nigeria
Regenxbio doses first patient in diabetic retinopathy trial - Investing.com
Regenxbio Advances Diabetic Retinopathy Gene Therapy Trial - TipRanks
REGENXBIO Announces First Patient Dosed in Phase IIb/III NAAVIGATE Trial of Surabgene Lomparvovec in Diabetic Retinopathy; Company to Receive $100 Million Milestone - The AI Journal
REGENXBIO doses first patient in Phase IIb/III trial for diabetic retinopathy therapy - Traders Union
$100M AbbVie payment backs REGENXBIO (RGNX) Phase IIb/III eye gene therapy - Stock Titan
REGENXBIO doses first patient in eye-disease gene therapy trial - Stock Titan
REGENXBIO Inc.(NasdaqGS: RGNX) added to Russell 2000 Growth Benchmark - marketscreener.com
REGENXBIO Inc.(NasdaqGS: RGNX) added to Russell 3000E Growth Benchmark - marketscreener.com
Regenxbio shares rise on plans to resubmit Navsunli BLA for MPS II - MSN
REGENXBIO Inc.(NasdaqGS: RGNX) added to Russell 3000 Growth Benchmark - marketscreener.com
Liquidity Mapping Around (RGNX) Price Events - Stock Traders Daily
Regenxbio: 'Strong Buy' On FDA Course Reversal For NAVSUNLI And Potential AA DMD Filing - Seeking Alpha
Enterprise value to EBITDA forward of REGENXBIO Inc. – NASDAQ:RGNX - TradingView
Enterprise value to revenue forward of REGENXBIO Inc. – NASDAQ:RGNX - TradingView
Enterprise value to revenue forward of REGENXBIO, Inc. – MUN:RB0 - TradingView
Enterprise value to EBITDA forward of REGENXBIO, Inc. – MUN:RB0 - TradingView
Enterprise value to EBIT forward of REGENXBIO, Inc. – MUN:RB0 - TradingView
Price to sales forward of REGENXBIO Inc. – NASDAQ:RGNX - TradingView
Price to book forward of REGENXBIO, Inc. – MUN:RB0 - TradingView
Price to earnings forward of REGENXBIO Inc. – NASDAQ:RGNX - TradingView
REGENXBIO, Inc. Actuals & Estimates (NASDAQ:RGNX) - TradingView
REGENXBIO, Inc. Actuals & Estimates (DUS:RB0) - TradingView
Phase III wins in May span gene therapy, gout, and pancreatic cancer - BioWorld News
What's Going On With Capricor Therapeutics Stock On Friday? - Sahm
REGENXBIO, Inc. Actuals & Estimates (LS:A140E0) - TradingView
FDA Commissioner Refers To Rare Disease Drug With Associated Morbidity: Analysts Are Divided If Makary Meant Regenxbio Or Uniqure’s Experimental Therapy - Stocktwits
RGNX Forecast — Price Target — Prediction for 2027 - TradingView
FDA Clears Path for NAVSUNLI BLA Resubmission in MPS II, No Additional Studies Required - NeurologyLive
H.C. Wainwright reiterates Regenxbio stock rating on trial completion - Investing.com UK
H.C. Wainwright reiterates Regenxbio stock rating on trial completion By Investing.com - Investing.com South Africa
Morgan Stanley Maintains Regenxbio(RGNX.US) With Buy Rating, Maintains Target Price $16 - Moomoo
Regenxbio completes dosing in Duchenne gene therapy study - The Pharmaletter
REGENXBIO Inc. (RGNX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
RGNX Reiterated by HC Wainwright & Co. -- Price Target Maintained at $26 - GuruFocus
What’s next in line for FDA reversals after UniQure and Regenxbio - Seeking Alpha
REGENXBIO completes RGX-202 dosing in DMD study - grafa.com
1.18%
2.48%
大文字化:
|
ボリューム (24 時間):